Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06055452
PHASE4

Effects of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Sponsor: China National Center for Cardiovascular Diseases

View on ClinicalTrials.gov

Summary

In this multicenter, randomized, placebo-controlled trial in pre-heat failure patients with hypertension and without diabetes, we will enroll 120 eligible patients to randomized to receive placebo or engagliflozin (10mg/d) for follow them for 6 months. The primary endpoint is the left atrial volume index, which reflects left ventricular diastolic function. We sought to comprehensively evaluate the effect of engagliflozin on the structure and function and explore its underlying mechanisms.

Official title: Effects and Mechanism of SGLT2 Inhibitors in Pre-heart Failure Populations With Hypertension

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2024-01-19

Completion Date

2026-12-31

Last Updated

2026-03-05

Healthy Volunteers

No

Interventions

DRUG

Empagliflozin 10 MG

Each participant in the empagliflozin treatment group takes a daily dose of 10mg.

DRUG

Placebo

Each participant in the placebo group takes matching placebo.

Locations (2)

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, Beijing Municipality, China

Fuwai Hospital Chinese Academy of Medial Sciences, Shenzhen

Shenzhen, Guangdong, China